drugset / Trial / NCT04749914

A Study of Lasmiditan in Healthy Volunteers

NCT04749914

Phase 1 Completed 97 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of the study is to investigate the blood concentrations of dabigatran etexilate and rosuvastatin when taken alone compared to when taken together with lasmiditan in healthy participants. The safety and tolerability of dabigatran etexilate or rosuvastatin in combination with lasmiditan will also be evaluated in healthy participants. The study has two parts. Each part will last up to 17 days, not including screening.

Timeline

Start
2021-02-15
Primary completion
2021-07-06
Completion
2021-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg Oral
Subject Lasmiditan Small molecule 200 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral

Indications

No indication recorded.